DBV Technologies to Join Upcoming Investor Conferences

DBV Technologies, a biopharmaceutical company listed on Euronext and Nasdaq, is set to participate in two major investor conferences this May. Daniel Tassé, the company's Chief Executive Officer, will be presenting at these events to discuss the company's progress and future plans.

The first event is the Citizens JMP Life Sciences Conference, scheduled for May 13, 2024. This conference will take place at the Hilton Midtown Hotel in New York, NY. Daniel Tassé will engage in a fireside chat at 11:00am ET, providing insights into the company's current focus areas and developments.

The second event is the H.C. Wainwright BioConnect Conference on May 20, 2024. This conference will be held at the NASDAQ World Headquarters, also in New York, NY. Tassé will again participate in a fireside chat, this time at 12:00pm ET, discussing the company's initiatives and answering questions from the investment community.

Both presentations will be available via live webcast on DBV Technologies' website under the Investors section. The webcasts will also be accessible for replay for 90 days following each event.

DBV Technologies is dedicated to developing treatments for food allergies and other immunologic conditions that are currently underserved. The company's proprietary technology platform, Viaskin™, is at the forefront of this research. Viaskin™ aims to address food allergies by introducing microgram amounts of an allergen to the immune system through the skin, a method known as epicutaneous immunotherapy (EPIT™). This approach seeks to desensitize individuals to allergens, thereby potentially transforming the management of food allergies.

Food allergies affect millions of people worldwide, including many young children. Symptoms can vary widely, from mild reactions to severe, life-threatening anaphylaxis. DBV Technologies' focus is on alleviating these conditions through its innovative Viaskin™ platform. The company is currently conducting clinical trials for Viaskin Peanut, targeting peanut allergies in toddlers aged 1 to 3 years and children aged 4 to 7 years.

Headquartered in Montrouge, France, DBV Technologies also has operations in North America, based in Warren, NJ. The company's shares are traded on Euronext Paris under the ticker symbol DBV, and its American Depositary Shares (ADSs) are traded on the Nasdaq Global Select Market under the ticker symbol DBVT.

For additional information about DBV Technologies and its groundbreaking work in immunotherapy, you can visit their website and follow them on social media platforms like X (formerly Twitter) and LinkedIn. Viaskin and EPIT are registered trademarks of DBV Technologies.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!